Literature DB >> 23298840

Reducing cardiovascular mortality in chronic kidney disease: something borrowed, something new.

L Darryl Quarles1.   

Abstract

CLINICAL VIGNETTE: A 48-year-old man with chronic kidney disease stage five due to type II diabetes mellitus and hypertension was referred for hemodialysis initiation. His physical exam showed a blood pressure of 150/80, normal fundi, a positive fourth heart sound (S4), and trace pedal edema. Moderate aortic calcification was present on prior chest X-ray. The ECG showed left ventricle hypertrophy by voltage and slight prolongation of the QT interval. Medications included chlorthalidone, amlodipine, carvedilol, cholecalciferol, erythropoietin, and a phosphate binder. What additional therapy should be initiated to reduce vascular calcifications and cardiovascular mortality?

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23298840      PMCID： PMC3561828          DOI： 10.1172/JCI67203

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


  26 in total

1.  Aldosterone blockade and vascular calcification in hemodialysis patients.

Authors:  Kosaku Nitta; Takashi Akiba; Hiroshi Nihei
Journal:  Am J Med       Date:  2003-08-15       Impact factor: 4.965

2.  FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality.

Authors:  Victoria Shalhoub; Edward M Shatzen; Sabrina C Ward; James Davis; Jennitte Stevens; Vivian Bi; Lisa Renshaw; Nessa Hawkins; Wei Wang; Ching Chen; Mei-Mei Tsai; Russell C Cattley; Thomas J Wronski; Xuechen Xia; Xiaodong Li; Charles Henley; Michael Eschenberg; William G Richards
Journal:  J Clin Invest       Date:  2012-06-25       Impact factor: 14.808

3.  Is it time for spironolactone therapy in dialysis patients?

Authors:  Adrian Covic; Paul Gusbeth-Tatomir; David J A Goldsmith
Journal:  Nephrol Dial Transplant       Date:  2006-01-31       Impact factor: 5.992

4.  Endogenous aldosterone is involved in vascular calcification in rat.

Authors:  Sheng-Ying Wu; Yan-Rong Yu; Yan Cai; Li-Xin Jia; Xiong Wang; Chuan-Shi Xiao; Chao-Shu Tang; Yong-Fen Qi
Journal:  Exp Biol Med (Maywood)       Date:  2011-12-20

Review 5.  Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease.

Authors:  Jean-Philippe Bertocchio; David G Warnock; Frederic Jaisser
Journal:  Kidney Int       Date:  2011-03-16       Impact factor: 10.612

6.  The inflammatory cytokines TWEAK and TNFα reduce renal klotho expression through NFκB.

Authors:  Juan A Moreno; Maria C Izquierdo; Maria D Sanchez-Niño; Beatriz Suárez-Alvarez; Carlos Lopez-Larrea; Aniela Jakubowski; Julia Blanco; Rafael Ramirez; Rafael Selgas; Marta Ruiz-Ortega; Jesus Egido; Alberto Ortiz; Ana B Sanz
Journal:  J Am Soc Nephrol       Date:  2011-06-30       Impact factor: 10.121

7.  Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling.

Authors:  Aline Martin; Shiguang Liu; Valentin David; Hua Li; Anastasios Karydis; Jian Q Feng; L Darryl Quarles
Journal:  FASEB J       Date:  2011-04-20       Impact factor: 5.191

8.  Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.

Authors:  James B Wetmore; Shiguang Liu; Ron Krebill; Rochelle Menard; L Darryl Quarles
Journal:  Clin J Am Soc Nephrol       Date:  2009-11-05       Impact factor: 8.237

9.  The prognostic importance of left ventricular geometry in uremic cardiomyopathy.

Authors:  R N Foley; P S Parfrey; J D Harnett; G M Kent; D C Murray; P E Barré
Journal:  J Am Soc Nephrol       Date:  1995-06       Impact factor: 10.121

10.  A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model.

Authors:  Bing Dai; Valentin David; Aline Martin; Jinsong Huang; Hua Li; Yan Jiao; Weikuan Gu; L Darryl Quarles
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240
View more
  5 in total

1.  Aberrant activation of Wnt pathways in arteries associates with vascular calcification in chronic kidney disease.

Authors:  Jingyi Liu; Lei Zhang; Yang Zhou; Dan Zhu; Qi Wang; Lirong Hao
Journal:  Int Urol Nephrol       Date:  2016-05-07       Impact factor: 2.370

2.  Effect of oral vitamin D analogs on mortality and cardiovascular outcomes among adults with chronic kidney disease: a meta-analysis.

Authors:  Michelle C Mann; Amy J Hobbs; Brenda R Hemmelgarn; Derek J Roberts; Sofia B Ahmed; Doreen M Rabi
Journal:  Clin Kidney J       Date:  2014-12-02

Review 3.  Optimal management of hyperphosphatemia in end-stage renal disease: an Indian perspective.

Authors:  Yogesh Nv Reddy; Varun Sundaram; Georgi Abraham; Prethivee Nagarajan; Yuvaram Nv Reddy
Journal:  Int J Nephrol Renovasc Dis       Date:  2014-10-23

4.  The Use of Aspirin to Reduce the Risk of Thrombotic Events in Patients With End-Stage Renal Disease: Protocol for a Randomized Controlled Trial.

Authors:  Tiago Lemos Cerqueira; Nathalie Monique Vandevelde; Armando Fartolino Guerrero; Clara Krystal Pérez Fermin; Ricardo Wang; Evelin Elfriede Balbino; Janis L Breeze; Paola Gonzalez Mego; Daniele Argentina Silva; Walid Ezzeldin Omer
Journal:  JMIR Res Protoc       Date:  2018-08-09

5.  The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to alkalinization-induced vascular calcification in vitro.

Authors:  Yaling Bai; Jinsheng Xu; Shuo Yang; Huiran Zhang; Lei He; Wei Zhou; Meijuan Cheng; Shenglei Zhang
Journal:  J Clin Lab Anal       Date:  2021-07-27       Impact factor: 2.352
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.